お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はHIV治療薬市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはHIV治療薬の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のHIV治療薬市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはHIV治療薬のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にHIV治療薬市場を分類しています。本研究に含まれる主な企業は：ViiV Healthcare、Gilead Sciences, Inc、Merck Sharp & Dohme Corp、Bristol-Myers Squibb Company、Janssen Pharmaceuticals, Inc.、Theratechnologies Inc.、Viatris Pharmaceuticals Inc.、Genentech, Inc.、AbbVie Inc.

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    Integrase Inhibitors
    Combination HIV Medicines
    Others

用途別の市場セグメント：
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies
    Others

本レポートの詳細内容
世界のHIV治療薬市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、HIV治療薬タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のHIV治療薬収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のHIV治療薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、HIV治療薬市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

HIV治療薬のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：HIV治療薬のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：HIV治療薬の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章HIV治療薬企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：HIV治療薬の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：HIV治療薬の主要企業の概要を提供し、製品の説明と仕様、HIV治療薬の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

HIV/AIDS is one of the most serious chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease.

Market Analysis and Insights: Global Drugs for HIV Market
The global Drugs for HIV market is projected to grow from US$ 32440 million in 2024 to US$ 45750 million by 2030, at a Compound Annual Growth Rate (CAGR) of 5.9% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Drugs for HIV market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Drugs for HIV, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Drugs for HIV, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drugs for HIV revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Drugs for HIV market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Drugs for HIV revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
    ViiV Healthcare
    Gilead Sciences, Inc
    Merck Sharp & Dohme Corp
    Bristol-Myers Squibb Company
    Janssen Pharmaceuticals, Inc.
    Theratechnologies Inc.
    Viatris Pharmaceuticals Inc.
    Genentech, Inc.
    AbbVie Inc.

Segment by Type
    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    Integrase Inhibitors
    Combination HIV Medicines
    Others

Segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Drugs for HIV in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for HIV companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for HIV revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Drugs for HIV Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    Table 3. Key Players of Integrase Inhibitors
    Table 4. Key Players of Combination HIV Medicines
    Table 5. Key Players of Others
    Table 6. Global Drugs for HIV Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 7. Global Drugs for HIV Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Drugs for HIV Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Drugs for HIV Market Share by Region (2019-2024)
    Table 10. Global Drugs for HIV Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Drugs for HIV Market Share by Region (2025-2030)
    Table 12. Drugs for HIV Market Trends
    Table 13. Drugs for HIV Market Drivers
    Table 14. Drugs for HIV Market Challenges
    Table 15. Drugs for HIV Market Restraints
    Table 16. Global Drugs for HIV Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Drugs for HIV Revenue Share by Players (2019-2024)
    Table 18. Global Top Drugs for HIV by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for HIV as of 2023)
    Table 19. Global Drugs for HIV Industry Ranking 2022 VS 2023 VS 2024
    Table 20. Global 5 Largest Players Market Share by Drugs for HIV Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Global Key Players of Drugs for HIV, Headquarters and Area Served
    Table 22. Global Key Players of Drugs for HIV, Product and Application
    Table 23. Global Key Players of Drugs for HIV, Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Drugs for HIV Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Drugs for HIV Revenue Market Share by Type (2019-2024)
    Table 27. Global Drugs for HIV Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Drugs for HIV Revenue Market Share by Type (2025-2030)
    Table 29. Global Drugs for HIV Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Drugs for HIV Revenue Share by Application (2019-2024)
    Table 31. Global Drugs for HIV Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Drugs for HIV Revenue Share by Application (2025-2030)
    Table 33. North America Drugs for HIV Market Size by Type (2019-2024) & (US$ Million)
    Table 34. North America Drugs for HIV Market Size by Type (2025-2030) & (US$ Million)
    Table 35. North America Drugs for HIV Market Size by Application (2019-2024) & (US$ Million)
    Table 36. North America Drugs for HIV Market Size by Application (2025-2030) & (US$ Million)
    Table 37. North America Drugs for HIV Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. North America Drugs for HIV Market Size by Country (2019-2024) & (US$ Million)
    Table 39. North America Drugs for HIV Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Europe Drugs for HIV Market Size by Type (2019-2024) & (US$ Million)
    Table 41. Europe Drugs for HIV Market Size by Type (2025-2030) & (US$ Million)
    Table 42. Europe Drugs for HIV Market Size by Application (2019-2024) & (US$ Million)
    Table 43. Europe Drugs for HIV Market Size by Application (2025-2030) & (US$ Million)
    Table 44. Europe Drugs for HIV Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Europe Drugs for HIV Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Europe Drugs for HIV Market Size by Country (2025-2030) & (US$ Million)
    Table 47. China Drugs for HIV Market Size by Type (2019-2024) & (US$ Million)
    Table 48. China Drugs for HIV Market Size by Type (2025-2030) & (US$ Million)
    Table 49. China Drugs for HIV Market Size by Application (2019-2024) & (US$ Million)
    Table 50. China Drugs for HIV Market Size by Application (2025-2030) & (US$ Million)
    Table 51. Asia Drugs for HIV Market Size by Type (2019-2024) & (US$ Million)
    Table 52. Asia Drugs for HIV Market Size by Type (2025-2030) & (US$ Million)
    Table 53. Asia Drugs for HIV Market Size by Application (2019-2024) & (US$ Million)
    Table 54. Asia Drugs for HIV Market Size by Application (2025-2030) & (US$ Million)
    Table 55. Asia Drugs for HIV Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 56. Asia Drugs for HIV Market Size by Region (2019-2024) & (US$ Million)
    Table 57. Asia Drugs for HIV Market Size by Region (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Drugs for HIV Market Size by Type (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Drugs for HIV Market Size by Type (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Drugs for HIV Market Size by Application (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Drugs for HIV Market Size by Application (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Drugs for HIV Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 63. Middle East, Africa, and Latin America Drugs for HIV Market Size by Country (2019-2024) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Drugs for HIV Market Size by Country (2025-2030) & (US$ Million)
    Table 65. ViiV Healthcare Company Details
    Table 66. ViiV Healthcare Business Overview
    Table 67. ViiV Healthcare Drugs for HIV Product
    Table 68. ViiV Healthcare Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 69. ViiV Healthcare Recent Developments
    Table 70. Gilead Sciences, Inc Company Details
    Table 71. Gilead Sciences, Inc Business Overview
    Table 72. Gilead Sciences, Inc Drugs for HIV Product
    Table 73. Gilead Sciences, Inc Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 74. Gilead Sciences, Inc Recent Developments
    Table 75. Merck Sharp & Dohme Corp Company Details
    Table 76. Merck Sharp & Dohme Corp Business Overview
    Table 77. Merck Sharp & Dohme Corp Drugs for HIV Product
    Table 78. Merck Sharp & Dohme Corp Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 79. Merck Sharp & Dohme Corp Recent Developments
    Table 80. Bristol-Myers Squibb Company Company Details
    Table 81. Bristol-Myers Squibb Company Business Overview
    Table 82. Bristol-Myers Squibb Company Drugs for HIV Product
    Table 83. Bristol-Myers Squibb Company Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 84. Bristol-Myers Squibb Company Recent Developments
    Table 85. Janssen Pharmaceuticals, Inc. Company Details
    Table 86. Janssen Pharmaceuticals, Inc. Business Overview
    Table 87. Janssen Pharmaceuticals, Inc. Drugs for HIV Product
    Table 88. Janssen Pharmaceuticals, Inc. Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 89. Janssen Pharmaceuticals, Inc. Recent Developments
    Table 90. Theratechnologies Inc. Company Details
    Table 91. Theratechnologies Inc. Business Overview
    Table 92. Theratechnologies Inc. Drugs for HIV Product
    Table 93. Theratechnologies Inc. Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 94. Theratechnologies Inc. Recent Developments
    Table 95. Viatris Pharmaceuticals Inc. Company Details
    Table 96. Viatris Pharmaceuticals Inc. Business Overview
    Table 97. Viatris Pharmaceuticals Inc. Drugs for HIV Product
    Table 98. Viatris Pharmaceuticals Inc. Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 99. Viatris Pharmaceuticals Inc. Recent Developments
    Table 100. Genentech, Inc. Company Details
    Table 101. Genentech, Inc. Business Overview
    Table 102. Genentech, Inc. Drugs for HIV Product
    Table 103. Genentech, Inc. Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 104. Genentech, Inc. Recent Developments
    Table 105. AbbVie Inc. Company Details
    Table 106. AbbVie Inc. Business Overview
    Table 107. AbbVie Inc. Drugs for HIV Product
    Table 108. AbbVie Inc. Revenue in Drugs for HIV Business (2019-2024) & (US$ Million)
    Table 109. AbbVie Inc. Recent Developments
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Drugs for HIV Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Drugs for HIV Market Share by Type: 2023 VS 2030
    Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
    Figure 4. Integrase Inhibitors Features
    Figure 5. Combination HIV Medicines Features
    Figure 6. Others Features
    Figure 7. Global Drugs for HIV Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Drugs for HIV Market Share by Application: 2023 VS 2030
    Figure 9. Hospital Pharmacies Case Studies
    Figure 10. Retail Pharmacies Case Studies
    Figure 11. Online Pharmacies Case Studies
    Figure 12. Others Case Studies
    Figure 13. Drugs for HIV Report Years Considered
    Figure 14. Global Drugs for HIV Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Drugs for HIV Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Drugs for HIV Market Share by Region: 2023 VS 2030
    Figure 17. Global Drugs for HIV Market Share by Players in 2023
    Figure 18. Global Top Drugs for HIV Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for HIV as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Drugs for HIV Revenue in 2023
    Figure 20. North America Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Drugs for HIV Market Share by Type (2019-2030)
    Figure 22. North America Drugs for HIV Market Share by Application (2019-2030)
    Figure 23. North America Drugs for HIV Market Share by Country (2019-2030)
    Figure 24. United States Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Canada Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Europe Drugs for HIV Market Size YoY (2019-2030) & (US$ Million)
    Figure 27. Europe Drugs for HIV Market Share by Type (2019-2030)
    Figure 28. Europe Drugs for HIV Market Share by Application (2019-2030)
    Figure 29. Europe Drugs for HIV Market Share by Country (2019-2030)
    Figure 30. Germany Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. France Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. U.K. Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Italy Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Russia Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Nordic Countries Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. China Drugs for HIV Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. China Drugs for HIV Market Share by Type (2019-2030)
    Figure 38. China Drugs for HIV Market Share by Application (2019-2030)
    Figure 39. Asia Drugs for HIV Market Size YoY (2019-2030) & (US$ Million)
    Figure 40. Asia Drugs for HIV Market Share by Type (2019-2030)
    Figure 41. Asia Drugs for HIV Market Share by Application (2019-2030)
    Figure 42. Asia Drugs for HIV Market Share by Region (2019-2030)
    Figure 43. Japan Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. South Korea Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. China Taiwan Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. India Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Australia Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Drugs for HIV Market Size YoY (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Drugs for HIV Market Share by Type (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Drugs for HIV Market Share by Application (2019-2030)
    Figure 52. Middle East, Africa, and Latin America Drugs for HIV Market Share by Country (2019-2030)
    Figure 53. Brazil Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Mexico Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Turkey Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Saudi Arabia Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Israel Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. GCC Countries Drugs for HIV Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. ViiV Healthcare Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 60. Gilead Sciences, Inc Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 61. Merck Sharp & Dohme Corp Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 62. Bristol-Myers Squibb Company Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 63. Janssen Pharmaceuticals, Inc. Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 64. Theratechnologies Inc. Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 65. Viatris Pharmaceuticals Inc. Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 66. Genentech, Inc. Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 67. AbbVie Inc. Revenue Growth Rate in Drugs for HIV Business (2019-2024)
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed